Brevera Study

  • Research type

    Research Study

  • Full title

    A RETROSPECTIVE/PROSPECTIVE STUDY TO EVALUATE THE PERFORMANCE AND OPERATION OF THE BREVERA™ BREAST BIOPSY SYSTEM

  • IRAS ID

    222758

  • Contact name

    William Teh

  • Contact email

    william.teh@nhs.net

  • Sponsor organisation

    Hologic, Inc.

  • Duration of Study in the UK

    0 years, 7 months, 1 days

  • Research summary

    The Brevera study is a Retrospective/Prospective Study to Evaluate the Performance and Operation of the Brevera Breast Biopsy System.

    The objective of the study is to obtain clinical/operational data and feedback on the Brevera Breast Biopsy System.

    The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. The system is designed for biopsy and for radiographic image acquisition and display only.

    Up to 500 women with suspicious findings on previous imaging (e.g. mammographic, Magnetic Resonance Imaging or Conventional Diagnostic Ultrasound imaging (screening or Diagnostic)) who are sent for biopsy will be enrolled in up to 10 sites across The Netherlands, Italy, France, Germany, Spain and the United Kingdom.

    The duration of the study is expected to take 3 months, including enrollment period. The participation of the subject consists of 1 visit. Once the subject has completed the Brevera procedure, a questionnaire will be given to the subject and after completion her direct participation in the study is concluded.

  • REC name

    East Midlands - Nottingham 1 Research Ethics Committee

  • REC reference

    17/EM/0073

  • Date of REC Opinion

    3 Oct 2017

  • REC opinion

    Further Information Favourable Opinion